Bradykinin Fragment 1-5
Bradykinin Fragment 1-5 structure
|
Common Name | Bradykinin Fragment 1-5 | ||
|---|---|---|---|---|
| CAS Number | 23815-89-6 | Molecular Weight | 572.65600 | |
| Density | 1.46g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C27H40N8O6 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
Use of Bradykinin Fragment 1-5Bradykinin (1-5) is a major stable metabolite of Bradykinin, formed by the proteolytic action of angiotensin-converting enzyme (ACE). |
| Name | 2-[[2-[[1-[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Bradykinin (1-5) is a major stable metabolite of Bradykinin, formed by the proteolytic action of angiotensin-converting enzyme (ACE). |
|---|---|
| Related Catalog | |
| In Vivo | Bradykinin is a short-lived vasoactive peptide, with a reported half-life in vivo of 17 s, that is rapidly metabolized in the circulation to Bradykinin (1-5). Bradykinin (1-5), the product of two sequential cleavages of Bradykinin by ACE at the Pro7-Phe8 and Phe5-Ser6bonds, has been identified as the major stable metabolite of Bradykinin in vivo in human subjects, with a terminal half-life of minutes. Both Bradykinin and Bradykinin (1-5) inhibit α- and γ-thrombin-induced platelet aggregation (P<0.01 versus baseline). Bradykinin (1-5) inhibits γ-thrombin-induced platelet aggregation 50% at a calculated dose of 183±3 pmol/min. Neither Bradykinin nor Bradykinin (1-5) affects thrombin receptor-activating peptide-induced platelet aggregation, consistent with the hypothesis that Bradykinin and Bradykinin 1-5 inhibit thrombin-induced platelet aggregation by preventing cleavage of the thrombin receptor and liberation of thrombin receptor-activating peptide. Bradykinin (1-5) significantly attenuates α-thrombin-induced platelet aggregation but not TRAP 1-6-induced platelet aggregation. Bradykinin (1-5) potently inhibits γ-thrombin (500 nM)-induced platelet aggregation with an ED50 of 183±2 pmol/min[1]. |
| References |
| Density | 1.46g/cm3 |
|---|---|
| Molecular Formula | C27H40N8O6 |
| Molecular Weight | 572.65600 |
| Exact Mass | 572.30700 |
| PSA | 224.04000 |
| LogP | 1.03610 |
| Index of Refraction | 1.677 |
| InChIKey | USSUMSBPLJWFSZ-TUFLPTIASA-N |
| SMILES | NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NCC(=O)NC(Cc1ccccc1)C(=O)O |
| Storage condition | -20°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | F+ |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3.0 |
|
Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.
Clin. Pharmacol. Ther. 76(4) , 379-87, (2004) This study tested the hypothesis that angiotensin-converting enzyme (ACE) inhibitors potentiate activation of the kallikrein-kinin system during cardiopulmonary bypass (CPB).The effects of CPB on conc... |
|
|
Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.
Thromb. Haemost. 86(5) , 1296-304, (2001) Thrombostatins are a group of compounds based upon a breakdown product of bradykinin, RPPGF. They inhibit alpha-thrombin-induced platelet activation by binding to protease activated receptor 1 and, at... |
|
|
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.
J. Thromb. Haemost. 6(5) , 837-45, (2008) Novel pentapeptides called Thrombostatin FM compounds consisting mostly of D-isomers and unusual amino acids were prepared based upon the stable angiotensin converting enzyme breakdown product of brad... |
| Arg-pro-pro-gly-phe |
| Bradykinin Fragment-1-5 |
| 2-[2-({1-[1-(2-amino-5-carbamimidamidopentanoyl)pyrrolidine-2-carbonyl]pyrrolidin-2-yl}formamido)acetamido]-3-phenylpropanoic acid |
| Bradykinin: 1-5 |
| Bradykinin (1-5) |